Latest filing published 31 Jan 2019 for Opus Genetics, Inc., €7,997.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 11 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -71.9%Entry US$30.72 · Close at T+365 US$8.64
- +77.9%Entry US$17.03 · Close at T+365 US$30.30
- -33.0%Entry US$32.39 · Close at T+365 US$21.71
- +269.5%Entry US$8.94 · Close at T+365 US$33.03
- -33.3%Entry US$9.72 · Close at T+365 US$6.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Ben Gil Price: trading record in brief
Ben Gil Price has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Sarepta Therapeutics, Inc. and Opus Genetics, Inc. In total, 19 filings cover trades dated from 15 August 2008 to 29 January 2019.
Every open-market trade on record is a purchase: 11 purchases worth €227k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 8 share grants. In 2019 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €12k. Ninety days after publication, 11 purchases show a median change of +1.2%, with the price up in 55% of them. This is a record of the past, not a forecast.
On 31 January 2019 came the latest disclosure, an open-market purchase for €7,997 in Opus Genetics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Ben Gil Price
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 15,000 shares@ US$0.6094100.0% of flowCommon StockSEC:0001140361-19-002082:0Canonical exit: 29 Apr 2019 (T+90)
- 4,500 shares@ US$16.70100.0% of flowCommon StockSEC:0001209191-16-108952:0Canonical exit: 12 Jun 2016 (T+90)
- 1,000 shares0Common StockSEC:0001209191-16-104938:0
- 1,000 shares0Common StockSEC:0001325812-15-000021:0
- 1,000 shares0Common StockSEC:0000873303-14-000029:0
- 500 shares@ US$31.18Common StockSEC:0001181431-13-045716:0Canonical exit: 17 Nov 2013 (T+90)
- 1,000 shares0Common StockSEC:0001181431-13-033354:0
- 833 shares0Common StockSEC:0001181431-12-047608:0
- 30,000 shares@ US$1.30Common StockSEC:0000873303-12-000003:0Canonical exit: 12 Jun 2012 (T+90)
- 5,000 shares0Common StockSEC:0000873303-11-000033:0
- 20,000 shares@ US$1.50Common StockSEC:0000873303-11-000014:0Canonical exit: 5 Jul 2011 (T+90)
- 4,000 shares@ US$1.93Common StockSEC:0000873303-10-000050:0Canonical exit: 11 Nov 2010 (T+90)
- 7,000 shares@ US$1.44Common StockSEC:0000873303-10-000027:0Canonical exit: 9 Sept 2010 (T+90)
- 5,000 shares0Common StockSEC:0000873303-10-000021:0
- 40,000 shares@ US$1.36Common StockSEC:0001257957-10-000018:0Canonical exit: 11 Aug 2010 (T+90)
- 5,000 shares0Common StockSEC:0001257957-09-000038:0
- 30,000 shares@ US$0.6459Common StockSEC:0001257957-09-000021:0Canonical exit: 11 Jun 2009 (T+90)
- 20,400 shares@ US$0.6717Common StockSEC:0001257957-09-000021:1Canonical exit: 14 Jun 2009 (T+90)
- 6,582 shares@ US$1.22Common StockSEC:0001257957-08-000040:0Canonical exit: 13 Nov 2008 (T+90)
19 of 19 declarations
